199 related articles for article (PubMed ID: 33297669)
1. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.
Leeman-Neill RJ; Soderquist CR; Montanari F; Raciti P; Park D; Radeski D; Mansukhani MM; Murty VV; Hsiao S; Alobeid B; Bhagat G
Haematologica; 2022 Jan; 107(1):201-210. PubMed ID: 33297669
[TBL] [Abstract][Full Text] [Related]
2. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
Ramis-Zaldivar JE; Gonzalez-Farre B; Nicolae A; Pack S; Clot G; Nadeu F; Mottok A; Horn H; Song JY; Fu K; Wright G; Gascoyne RD; Chan WC; Scott DW; Feldman AL; Valera A; Enjuanes A; Braziel RM; Smeland EB; Staudt LM; Rosenwald A; Rimsza LM; Ott G; Jaffe ES; Salaverria I; Campo E
Haematologica; 2021 Oct; 106(10):2682-2693. PubMed ID: 33951889
[TBL] [Abstract][Full Text] [Related]
3. Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area.
Meer S; Perner Y; McAlpine ED; Willem P
Histopathology; 2020 Jan; 76(2):212-221. PubMed ID: 31361906
[TBL] [Abstract][Full Text] [Related]
4. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
Witte HM; Künstner A; Hertel N; Bernd HW; Bernard V; Stölting S; Merz H; von Bubnoff N; Busch H; Feller AC; Gebauer N
Blood Adv; 2022 Jan; 6(2):637-651. PubMed ID: 34714908
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases.
Morscio J; Dierickx D; Nijs J; Verhoef G; Bittoun E; Vanoeteren X; Wlodarska I; Sagaert X; Tousseyn T
Am J Surg Pathol; 2014 Jul; 38(7):875-86. PubMed ID: 24832164
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and genetic landscape of plasmablastic lymphoma in Taiwan.
Chen BJ; Hsieh TH; Yuan CT; Wang RC; Yang CF; Chuang WY; Su YZ; Ho CH; Lin CH; Chuang SS
Pathol Res Pract; 2024 Jan; 253():155059. PubMed ID: 38160484
[TBL] [Abstract][Full Text] [Related]
7. Plasmablastic lymphomas show restricted EBV latency profile and
Ramburan A; Kriel R; Govender D
Leuk Lymphoma; 2022 Feb; 63(2):370-376. PubMed ID: 34612761
[TBL] [Abstract][Full Text] [Related]
8. High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma.
Miao L; Guo N; Feng Y; Rao H; Wang F; Huang Q; Huang Y
Histopathology; 2020 Jan; 76(2):201-211. PubMed ID: 31348551
[TBL] [Abstract][Full Text] [Related]
9. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
Chapman JR; Bouska AC; Zhang W; Alderuccio JP; Lossos IS; Rimsza LM; Maguire A; Yi S; Chan WC; Vega F; Song JY
Br J Haematol; 2021 Sep; 194(5):870-878. PubMed ID: 34272731
[TBL] [Abstract][Full Text] [Related]
10. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.
Laurent C; Fabiani B; Do C; Tchernonog E; Cartron G; Gravelle P; Amara N; Malot S; Palisoc MM; Copie-Bergman C; Glehen AT; Copin MC; Brousset P; Pittaluga S; Jaffe ES; Coppo P
Haematologica; 2016 Aug; 101(8):976-84. PubMed ID: 27175027
[TBL] [Abstract][Full Text] [Related]
11. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.
Loghavi S; Alayed K; Aladily TN; Zuo Z; Ng SB; Tang G; Hu S; Yin CC; Miranda RN; Medeiros LJ; Khoury JD
J Hematol Oncol; 2015 Jun; 8():65. PubMed ID: 26055271
[TBL] [Abstract][Full Text] [Related]
12. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.
Frontzek F; Staiger AM; Zapukhlyak M; Xu W; Bonzheim I; Borgmann V; Sander P; Baptista MJ; Heming JN; Berning P; Wullenkord R; Erdmann T; Lutz M; Veratti P; Ehrenfeld S; Wienand K; Horn H; Goodlad JR; Wilson MR; Anagnostopoulos I; Lamping M; Gonzalez-Barca E; Climent F; Salar A; Castellvi J; Abrisqueta P; Menarguez J; Aldamiz T; Richter J; Klapper W; Tzankov A; Dirnhofer S; Rosenwald A; Mate JL; Tapia G; Lenz P; Miething C; Hartmann W; Chapuy B; Fend F; Ott G; Navarro JT; Grau M; Lenz G
Nat Commun; 2021 Aug; 12(1):5183. PubMed ID: 34465776
[TBL] [Abstract][Full Text] [Related]
13. Oral versus extra-oral plasmablastic lymphoma: A comparative analysis of 101 cases.
Meer S; Perner Y; Willem P
J Oral Pathol Med; 2022 Feb; 51(2):146-151. PubMed ID: 34910327
[TBL] [Abstract][Full Text] [Related]
14. Plasmablastic lymphoma: An update.
Bailly J; Jenkins N; Chetty D; Mohamed Z; Verburgh ER; Opie JJ
Int J Lab Hematol; 2022 Sep; 44 Suppl 1(Suppl 1):54-63. PubMed ID: 36074710
[TBL] [Abstract][Full Text] [Related]
15. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.
Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Loghavi S; Gomez Mediavilla A; Tonda R; Beltran S; Gut M; Pereña Gonzalez A; d'Ámore E; Visco C; Khoury JD; Montes-Moreno S
Haematologica; 2021 Apr; 106(4):1120-1128. PubMed ID: 32273478
[TBL] [Abstract][Full Text] [Related]
16. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.
Liu Z; Filip I; Gomez K; Engelbrecht D; Meer S; Lalloo PN; Patel P; Perner Y; Zhao J; Wang J; Pasqualucci L; Rabadan R; Willem P
Blood Cancer Discov; 2020 Jul; 1(1):112-125. PubMed ID: 33225311
[TBL] [Abstract][Full Text] [Related]
17. MYC status in HIV-associated plasmablastic lymphoma: dual-colour CISH, FISH and immunohistochemistry.
Pather S; Mashele T; Willem P; Patel M; Perner Y; Motaung M; Nagiah N; Waja F; Philip V; Lakha A; Hale MJ
Histopathology; 2021 Jul; 79(1):86-95. PubMed ID: 33450085
[TBL] [Abstract][Full Text] [Related]
18. Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis.
Koizumi Y; Imadome KI; Ota Y; Minamiguchi H; Kodama Y; Watanabe D; Mikamo H; Uehira T; Okada S; Shirasaka T
J Clin Immunol; 2018 May; 38(4):478-483. PubMed ID: 29687211
[TBL] [Abstract][Full Text] [Related]
19. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features.
Taddesse-Heath L; Meloni-Ehrig A; Scheerle J; Kelly JC; Jaffe ES
Mod Pathol; 2010 Jul; 23(7):991-9. PubMed ID: 20348882
[TBL] [Abstract][Full Text] [Related]
20. Primary plasmablastic lymphoma of the gastrointestinal tract: A series of 13 HIV-negative cases and a review of literature.
Fu Z; Wang H; Lauwers GY; Jiang K; Jayaratne NL; Bridglal S; Dong N; Wang E; Chen L; Barclift DP; Zhang L
Ann Diagn Pathol; 2023 Dec; 67():152204. PubMed ID: 37639839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
